Before the pandemic, we used genomics and machine learning to detect residual solid tumor.
Residual disease is cancer that remains after a treatment.
Patients with liquid tumors have benefited from a series of technical revolutions in residual disease detection.
But patients with solid tumors like breast cancer have been left behind. Until now.